CCR 20th Anniversary Commentary: BMS-247550—Microtubule Stabilization as Successful Targeted Therapy

In a landmark article published in the May 1, 2001, issue of Clinical Cancer Research , Lee and colleagues reported the original preclinical studies demonstrating anticancer activity of BMS-247550 (ixabepilone) against taxane-sensitive and taxane-resistant cancers. Subsequent clinical trials established the clinical efficacy of ixabepilone, leading to its regulatory approval for the treatment of drug-resistant metastatic or locally advanced breast cancers. Clin Cancer Res; 21(6); 1237–9. ©2015 AACR . See related article by Lee et al., Clin Cancer Res 2001;7(5) May 2001;1429–37